Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial

(2021) Gregory J. Riely et al.   Cancer Discovery

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

(2021) Francois Gonzalvez et al.   Cancer Discovery

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

(2021) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

(2020) Zofia Piotrowska et al.   JOURNAL OF CLINICAL ONCOLOGY

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

(2020) Xiuning Le et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

(2020) Guangjian Yang et al.   LUNG CANCER

1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

(2020) A. Prelaj et al.   ANNALS OF ONCOLOGY

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

(2019) Wenfeng Fang et al.   BMC CANCER

OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan

(2019) H. Udagawa et al.   Journal of Thoracic Oncology

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

(2019) B. van Veggel et al.   LUNG CANCER

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

(2018) Jonathan W. Riess et al.   Journal of Thoracic Oncology

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

(2018) Marcelo Vailati Negrao et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

(2018) Seonggyu Byeon et al.   Cancer Research and Treatment

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Uncommon EGFR mutations in advanced non-small cell lung cancer

(2017) Grainne M. O’Kane et al.   LUNG CANCER

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

(2014) V. Hirsh et al.   Current Oncology

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

(2014) Fiona Blackhall et al.   Journal of Thoracic Oncology

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER